Stockscreener 앱 받기
56.74
1.53%
-0.88
시장 영업 전:
56.74
Kiniksa Pharmaceuticals International Plc 주식(KNSA)의 최신 뉴스
Why Kiniksa Pharmaceuticals (KNSA) Is Up 5.4% After Raising 2026 Revenue Guidance And What's Next - simplywall.st
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider John Paolini Sells 58,424 Shares - MarketBeat
Kiniksa (NASDAQ: KNSA) CMO sells shares after exercising 58,424 options - Stock Titan
Why Kiniksa Pharmaceuticals International stock raced nearly 24% higher today - MSN
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Kornitzer Capital Management Inc. KS Purchases New Shares in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International plc Files 8-K: Announces Consulting Agreement Details and Company Information (April 30, 2026) - Minichart
Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat - MSN
Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance - Yahoo Finance
Sanj Patel Sells 48,565 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals CSO Resigns and Shifts to Advisor - TipRanks
Kiniksa Pharmaceuticals (KNSA) insider sale notice lists 58,424 shares - Stock Titan
Kiniksa (NASDAQ: KNSA) CSO Tessari resigns, signs $450/hour consulting deal - Stock Titan
Kiniksa (NASDAQ: KNSA) CEO Sanj K. Patel exercises options, sells 48,565 shares under 10b5-1 plan - Stock Titan
KNSA SEC FilingsKiniksa Pharmaceuticals International, plc 10-K, 10-Q, 8-K Forms - Stock Titan
Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results - Insider Monkey
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $1,217,601.44 in Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $115,635.41 in Stock - MarketBeat
Sanj Patel Sells 483,654 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa (NASDAQ: KNSA) CEO’s plan-based option exercises and 508K share sales detailed - Stock Titan
Pictet Asset Management Holding SA Has $32.49 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
KNSA Maintained by Citigroup -- Price Target Raised to $60 - GuruFocus
KNSA Maintained by Canaccord Genuity -- Price Target Raised to $64 - GuruFocus
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $656,260, According to a Recent SEC Filing - marketscreener.com
Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells 13,099 Shares of Stock - MarketBeat
Kiniksa (KNSA) director Quart exercises options, sells 13,099 shares under 10b5-1 plan - Stock Titan
KNSA Maintained by Wedbush -- Price Target Raised to $59.00 - GuruFocus
Kiniksa Pharmaceuticals International, plc (KNSA) tops Q1 earnings and revenue estimates - MSN
KNSA Maintained by Wells Fargo -- Price Target Raised to $57 - GuruFocus
Wedbush Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price - MarketBeat
Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation (KNSA) - Seeking Alpha
9 Best Drug Stocks to Buy According to Analysts - Insider Monkey
Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earning - GuruFocus
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High Following Strong Earnings - MarketBeat
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today - The Motley Fool
Is Kiniksa Pharmaceuticals International PLC (KNSA) Overvalued A - GuruFocus
Kiniksa Pharmaceuticals International Q1 2026 Earnings Call Transcript - MarketBeat
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today - The Motley Fool
KNSA Stock Soars 16.9% Following Recent Developments - GuruFocus
Kiniksa Pharmaceuticals (KNSA) Hits 52-Week High After Strong Q1 2026 Results - GuruFocus
KNSA Stock Jumps As Arcalyst Outlook Tops $1B Target - timothysykes.com
Kiniksa (NASDAQ: KNSA) insider sale and cashless exercise flagged in Form 144 - Stock Titan
ARCALYST sales lift Kiniksa (NASDAQ: KNSA) Q1 2026 profit and cash - Stock Titan
KNSA Maintains Buy Rating -- Price Target Raised to $71.00 by Je - GuruFocus
KNSA Stock Rallies As Wedbush Hikes Price Target On Arcalyst Momentum - StocksToTrade
KNSA Stock Surges 19.3% Amid Positive Developments - GuruFocus
Kiniksa posts Q1 beat thanks to Regeneron drug (KNSA:NASDAQ) - Seeking Alpha
KNSA Stock Climbs As Arcalyst Momentum Fuels Bullish Targets - StocksToTrade
Kiniksa Pharmaceuticals International, plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:KNSA) 2026-04-28 - Seeking Alpha
KNSA Stock Climbs As Analysts Hike Targets On Arcalyst Growth - timothysykes.com
Kiniksa Pharmaceuticals International Q1 Earnings Call Highlights - Yahoo Finance
Kiniksa Pharma Jumps On Q1 Revenue Growth; Lifts FY26 Revenue Guidance - RTTNews
KNSA Reports Strong Q1 Revenue Growth Amid ARCALYST Adoption - GuruFocus
Kiniksa Pharmaceuticals International (KNSA) Reports Q1 2026 Numbers - AlphaStreet
KNSA Expects Higher Revenue Projections for ARCALYST in 2026 - GuruFocus
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Kiniksa Pharmaceuticals Q1 Earnings, Revenue Rise; 2026 Arcalyst Revenue Outlook Raised - marketscreener.com
0.67%
2.13%
자본화:
|
볼륨(24시간):